Xiuning Le MD PhD (@LeXiuning) ranks #30 among US lung cancer KOLs on X in 2026, by engagement from fellow physicians. 13 physicians shared, quoted or replied to their posts this year. Most-discussed trials in 2026: HARMONi. CMS Open Payments lists $96,303 in 2025 general payments.
At a Glance
- 1 posts naming a trial in 2026
- 1 trials discussed by name
- 4 colleague posts sharing slides from Xiuning Le MD PhD's presentations
- Lung Cancer: US #30 · 13 physicians engaged
- Presented at WCLC 2026, ESMO 2026, ASCO 2026 in 2026
- CMS Open Payments lists $96,303 in 2025 general payments.
This Month
What Xiuning Le MD PhD has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Lung Cancer | #30 | — | 13 | 16 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Xiuning Le MD PhD presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- WCLC 2026 · Mini oral (MO12.04)SOHO-01: Molecular Landscape of Acquired Resistance to Sevabertinib in HER2-mutant NSCLCSOHO-01 trial profile → · Source: @HHorinouchi on X ↗
- ESMO 2026 · Poster (2712P)SOHO-01: Updated Efficacy and Safety of Sevabertinib in Advanced HER2-Mutant NSCLC, Including First-Line Patients and Those With Active Brain MetastasesSOHO-01 trial profile → · Source: @HHorinouchi on X ↗
- ASCO 2026 · Poster (8641)ABN401: Phase 2 Efficacy, Safety, and PK in Advanced Solid Tumors with c-MET DysregulationSource: @HHorinouchi on X ↗
- ESMO 2026 · DiscussantRapid oral abstracts on EGFR-mutant NSCLCSource: @StephenVLiu on X ↗
What Colleagues Are Saying About Xiuning Le MD PhD
2026 posts by fellow physicians that mention @LeXiuning, quoted word for word.
💥 Beyond traditional ADCs at #ELCC26! @LeXiuning ▪️Masked ADCs → tumor-activated targeting ▪️Nanobodies & peptides: better penetration, new epitopes ▪️Bicycle toxin conjugates: ultra-small, fast delivery 🎯 Innovation across 3 axes: target, linker, payload From ADCs to “anything-drug conjugates” @OncoAlert @myESMO @OncoReporte @_SEOM @gecp_org @Lung_Cancers
🆙 #ASCO26 Develp Tx Rapid Oral Abstract Session 🔥BH-30643 (Macrocyclic Non-Covalent OMNI-EGFR Inhibitor): First-in-Human Trial in EGFRm NSCLC 🎙️ @LeXiuning @HHorinouchi 🔢3014 ☑️NCT06706076 🔗 https://t.co/EPd8fWNCOS #LCSM @OncoAlert @Larvol @ASCO https://t.co/zOiQ7pPAME https://t.co/1P48yj7Itw
#ESMO26 Dr. @LeXiuning discusses rapid oral abstracts on EGFR mutant NSCLC, surveying current landscape and refinement - can ctDNA be used to escalate care? Can we streamline supportive measures to reduce EGFR-related toxicity? #ESMOAmbassadors https://t.co/IDemZ4HMjf
#ESMO26 Rapid #NSCLC oral presentations Great discussions by @LeXiuning on #EGFR 1L NSCLC based on #ctDNA results and Dr. Janne on #HER2 1L Zongertinib vs Sevabertinib vs T-DXd and mutation profile in #ALK fusion NSCLC #lorlatinib @OncoAlert @myESMO @ASCO @_SEOM @brunolarvol 👇🏽👇🏽
🧬 @LeXiuning giving a comprehensive discussion of ctDNA dynamics and adaptive intensification regimen in patients with EGFRmut lung cancer. Bottom line: combination regimens are default in first-line. #ESMO26 #LCSM https://t.co/bvJB6hFDJX
Very thoughtful discussion by @LeXiuning on the potential integration of baseline and clearance of ctDNA in the strategy of EGFRm NSCLC. @myESMO @OncoAlert #ESMO2026 https://t.co/RjvCTOy40N
Xiuning Le MD PhD’s Presentations
Slides from Xiuning Le MD PhD’s 2026 presentations, as shared by physicians in the audience.
#ESMO26 Dr. @LeXiuning discusses rapid oral abstracts on EGFR mutant NSCLC, surveying current landscape and refinement - can ctDNA be used to escalate care? Can we streamline supportive measures to reduce EGFR-related toxicity? #ESMOAmbassadors https://t.co/IDemZ4HMjf
ctDNA with 1L EGFRmut regimens ❓what does it tell us ❓what does it add We already know: 🔸EGFR ctDNA +ve @ baseline = poorer prognosis 🔸 Clearing EGFR ctDNA with treatment = better prognosis 🔸 EGFR ctDNA -ve @ baseline = no additional benefit of chemo/osi or ami/laz over osi alone PACE-Lung: 🔹ctDNA +ve at baseline 🔹If also ctDNA after 4wks on Osi, add chemo (x4 cycles) 🔹 mPFS = 17.8m [similar to FL2] FLAURA-2: 🔹 Focus on ctDNA +ve at baseline popn 🔹Osi+chemo improves OS & PFS irrespective of ctDNA clearance 🔹ctDNA +ve at baseline is prognostic, not predictive What do we know now? 🤔 If EGFR ctDNA -ve at baseline (20% popn), prognosis is better, and adding chemotherapy to osimertinib, or using ami/laz instead of osimertinib add little (no) benefit 🤔 If EGFR ctDNA +ve at baseline (80% popn), prognosis is worse. However, clearance or not of ctDNA does not help us refine treatments 🤔 If EGFR ctDNA +ve at baseline, osi+chemo or ami/laz is better than Osimertinib alone Brilliant discussion by @LeXiuning 👏 #ESMO26 #LCSM
Very thoughtful discussion by @LeXiuning on the potential integration of baseline and clearance of ctDNA in the strategy of EGFRm NSCLC. @myESMO @OncoAlert #ESMO2026 https://t.co/RjvCTOy40N
Superb discussion by @LeXiuning at #ESMO26 on ctDNA-guided treatment selection in EGFRm NSCLC. Key message: Early ctDNA clearance is prognostic, but NOT predictive of benefit from adding chemotherapy. Even patients achieving clearance derive substantial PFS benefit from osimertinib + chemo (HR 0.51). Can we safely spare chemotherapy in selected patients? Promising hypothesis, but not yet proven. If ctDNA is not detectable upfront (20% pts) then 30 Months mPFS with Osi only! #ESMOAmbassador #LungCancer
Trials Xiuning Le MD PhD Discussed in 2026
| Trial | Posts | Rank among physicians posting | Latest |
|---|---|---|---|
| HARMONi | 1 | #14 of 16 | Aug 26, 2026 |
Xiuning Le MD PhD on HARMONi
😜 Are we ready for the era of #PD1×VEGF #bispecific immunotherapy? 📖 Now online in #LancetOncology: #HARMONi — #ivonescimab plus chemotherapy in patients with #EGFR-mutant #NSCLC after progression on EGFR TKI therapy. 👉 First global randomized phase 3 study of a PD1×VEGF bispecific antibody N = 438, with 23% of patients enrolled in the United States 👉 Progression-free survival: 6.8 vs 4.4 months, HR 0.52 👉 Overall survival: 16.8 vs 14.0 months, HR 0.79 👉 Encouraging evidence of protection against CNS progression 💡 HARMONi represents an important step in evaluating the potential of simultaneously targeting PD-(L1)1 and VEGF. I hope this will be the first of many positive global studies exploring PD-(L)1 × VEGF approaches for patients with lung cancer and other solid tumors. https://t.co/o76uqb8uQQ ❤️ my global col-investigators, @Tony_Calles @delvysra @MNagasaka @DrSanjayPopat @nicogirardcurie, Drs. Passaro, Cappuzzo, Zhang, and many others ❤️
Xiuning Le MD PhD’s Most-Engaged Posts in 2026
Their own 2026 posts that fellow physicians reposted most, quoted word for word.
At #ASCO26, the @UTMDAnderson Thoracic Medical Oncology Department will deliver an incredible 9 oral presentations💐💐💐 highlighting advances across ##EGFR, #HER2, #KRAS, #KEAP1/STK11, #SCLC, IO, #peri-operative, all lung cancer subgroups. For perspective, thoracic medical oncologists from China have 16 oral presentations. 👩⚕️🧑⚕️ 👩🔬🧑🔬Our entire MDA Thoracic team @FSkoulidis @NIVokes @LaurenByersMD @lungoncdoc Drs. Heymach, Cascone, Zhang, @mvnegrao @YYElamin @AnneTsao2 are deeply proud and excited 😀to help shape the future of lung cancer research and patient care alongside outstanding collaborators and industry partners.
Honored to be delivering two educational lectures at 🔜 #ELCC26 @myESMO🇩🇰 in Copenhagen. 📍 March 26. 👉Beyond traditional ADCs: Advances in targeting, conjugation, payload design, and emerging modalities 📍 March 28 👉Mechanisms of resistance: Lessons from EGFR-mutant and ALK-rearranged NSCLC 💐Grateful to the conference chairs @DrSanjayPopat @APassaroMD for your excellent work on organizing #ELCC26. 💗Looking forward to great discussions and connecting with global colleagues @HHorinouchi @ThomasW35874311 @Alfdoc2 @caliraf @tnewsomdavis @YYElamin @lungoncdoc
Industry Payments
CMS Open Payments · 2025 general payments
$96,303 across 88 payments